Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $10.05M gross proceeds from 8.57M shares and warrants, funding working capital and general corporate purposes.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $10.05M gross proceeds from 8.57M shares and warrants, funding working capital and general corporate purposes
- Additional 721,649 insider shares and warrants at $1.455, above the $1.05 institutional purchase price
- Common warrants cover 8.57M shares at $1.31, exercisable after six months and authorized-shareholder approval
- Potential dilution from 9.29M warrant shares plus 465,157 placement-agent warrant shares
- Placement fees include 7.0% cash commission, $100,950 expenses, and five-year warrants at $1.3125
Item 8.01 · Other Events
- Cardiff Oncology priced a securities offering on July 15, 2026
- Offering proceeds and security terms require review of Exhibit 99.1
- Capital raise may affect liquidity and shareholder dilution depending on offering structure
Item EX-99.1 · Exhibit EX-99.1
- $10 million registered direct offering, funding working capital and general corporate purposes
- 8,571,429 shares plus warrants sold at $1.05 per share and warrant, creating substantial equity dilution
- Officers and directors purchasing 731,707 shares plus warrants at $1.435 per share and warrant
- Warrants exercisable after six months and authorized-share increase, with $1.31 exercise price and five-and-one-half-year term
- Closing expected July 16, 2026, subject to customary conditions; proceeds support Phase 2 oncology development runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.